Therapeutic Programs
Skin-led programs addressing unmet clinical needs where delivery remains a critical barrier to therapeutic performance.
Stanford-Originated Precision Delivery Technology, Powered by Peptides
Precision Delivery for Health That Lasts.
Starting with skin, N1 Life engineers programmable peptide carriers to improve therapeutic performance across skin, the ocular surface, and mucosal tissues.
Scientific Foundation
Stanford-Originated Delivery Technology. Validated in Humans.
Founded by Stanford scientists, N1 Life has built a proprietary peptide delivery technology validated through in vitro models, in vivo studies, human skin testing, and clinical validation. This evidence base supports programs at different stages of development.
Molecular Engineering
Peptide carriers designed around the therapeutic molecule, target tissue, and required delivery behavior.
In Vitro and In Vivo Evidence
The underlying delivery technology evaluated across biological models before advancing to human studies.
Human Skin Validation
Penetration, retention, release, and tissue response measured directly in human skin.
Clinical Validation
Human evidence establishes the performance of the underlying delivery technology.
Validation describes the underlying technology, not every individual program.
How the Technology Works
Programmable Delivery, Engineered at the Molecular Level.
Each therapeutic and target tissue presents a different delivery challenge. N1 designs peptide carriers to control how an active is loaded, protected, transported, retained, and released.
Load the Active
Match the carrier to the physicochemical properties of the therapeutic and its intended formulation.
Protect Function
Preserve stability and biological activity throughout the delivery process.
Navigate the Barrier
Control transport across, or retention within, the target tissue barrier.
Target and Release
Tune delivery depth, tissue location, and release profile for the intended therapeutic effect.
- Surface Retention
- Target Tissue Delivery
- Controlled Local Release
Each human dataset refines carrier selection, predictive modeling, and the next delivery design.
The same design framework can be tuned for skin, the ocular surface, and mucosal tissues.
Human Surface Intelligence
Every Program Strengthens the Next.
Consumer health programs can move through shorter development cycles and generate human data sooner. These insights strengthen platform learning and inform therapeutic program design. Evidence from pipeline validation then upgrades the platform, improving the next generation of both consumer health and therapeutic programs.
Closed Learning System
Human Surface Intelligence-
Consumer Health Programs
Shorter development cycles create earlier opportunities for human learning.
-
Human Data
Delivery performance, tolerability, and product-use data expand the evidence base.
-
Platform Learning
New evidence refines carrier selection, formulation decisions, and predictive models.
-
Therapeutic Program
Platform learnings inform better delivery choices for drug programs.
-
Pipeline Validation
Each therapeutic program follows its own required validation path.
-
Platform Upgrade
Validated learnings improve the next generation of programs.
Consumer data informs therapeutic design. Each therapeutic program completes its own validation.
Where We Focus
Skin First.
A tissue-specific delivery platform for complex biological barriers.
Skin is N1’s primary focus because significant clinical needs remain unmet, and delivery continues to limit the performance of many promising therapeutics.
Accessible human tissue and measurable outcomes let us test delivery directly. These readouts inform both therapeutic and consumer health programs.
What We Tune
- Surface retention
- Target tissue depth
- Controlled local release
Beyond Skin
- Ocular Surface
- Mucosal Tissues
Our Programs
Building Programs Where Delivery Can Change the Outcome.
N1 advances selected therapeutic and consumer health programs where precision delivery can address meaningful unmet needs, improve product performance, and create a clear path toward clinical or commercial value.
Consumer Health Programs
Evidence-driven programs that translate N1’s delivery science into differentiated products while generating faster human learning.
Partnerships
Partnering to Solve Complex Delivery Challenges.
N1 works with pharmaceutical, biotech, clinical, and consumer health teams to apply peptide delivery science to meaningful development challenges. Engagements can begin with an active, a target tissue, or an early therapeutic concept.
Define the Delivery Challenge
Align on the active, target tissue, desired delivery profile, formulation requirements, and development objective.
Design and Validate
Select and optimize peptide carriers, then evaluate delivery behavior through the appropriate experimental and human tissue models.
Build the Evidence Path
Generate decision-ready evidence for formulation, therapeutic development, clinical planning, or product translation.
The Company
Science-Led. Translation-Focused.
Founded by Stanford scientists, N1 Life brings together expertise in peptide engineering, drug delivery, human biology, clinical development, and product innovation. We apply scientific rigor, proprietary human data, and inventive engineering to pursue breakthroughs in precision delivery for unmet clinical needs.
Meet the TeamScientific Rigor
Mechanistic research and disciplined validation underpin every technology and program decision.
Human Data Intelligence
Proprietary, high-dimensional human tissue data informs carrier design, predictive models, and program development.
Translational Execution
Cross-functional expertise connects peptide engineering with clinical and product development.
Insights
Advancing the Science of Precision Delivery.
Explore scientific perspectives, research and clinical updates, publications, and company news from N1 Life.
Science & Technology
Perspectives on peptide engineering, drug delivery, and biological barriers.
Research & Clinical Updates
Approved research findings, publications, presentations, and human validation updates.
Company News
Company milestones, program updates, media coverage, and announcements.
Work With N1
Bring Us the Delivery Challenge.
Talk with N1 about the active, target tissue, and evidence your program needs to move forward.
Let’s Talk Delivery